Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics ...

Denifanstat showed continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks, including 57% ...

On average, reduction in plasma neurofilament light levels was observed during the first 12 weeks of treatment, with a greater decline in ...

The trial met both co-primary endpoints with statistical significance in the intent-to-treat (ITT) population (n=108) at 6 months: mean change from baseline in best corrected visual acuity (BCVA) ...

In this study, Jose Molto and colleagues report data from a randomised open-label clinical trial showing of first-line dolutegravir/lamivudine treatment for HIV-1. They report that the treatment ...

CervoMed expects to present 24-week biomarker data at the Clinical Trials on Alzheimer's Disease conference in November 2026, with topline clinical results anticipated in the first quarter of 2027.

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting ...

Phase 2 expansions of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2) ± cemiplimab in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the ...

Denifanstat showed continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks, including 57% IGA success, 72% ...

In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patients; Denifans ...